U.S. Markets open in 4 hrs 7 mins

Should You Buy Novelion Therapeutics Inc (NVLN)?

Lester Strauss

Novelion Therapeutics Inc (NASDAQ:NVLN), a biotechnology company based in Canada, saw significant share price volatility over the past couple of months on the NasdaqGS, rising to the highs of $7.76 and falling to the lows of $4.41. This high level of volatility gives investors the opportunity to enter into the stock, and potentially buy at an artificially low price. A question to answer is whether NVLN’s current trading price of $4.41 reflective of the actual value of the small-cap? Or is it currently undervalued, providing us with the opportunity to buy? Let’s take a look at NVLN’s outlook and value based on the most recent financial data to see if there are any catalysts for a price change. See our latest analysis for NVLN

Is NVLN still cheap?

Good news, investors! NVLN is still a bargain right now. According to my valuation, the intrinsic value for the stock is $18.39, but it is currently trading at $4.41 on the share market, meaning that there is still an opportunity to buy now. Another thing to keep in mind is that NVLN’s share price is quite stable relative to the rest of the market, as indicated by its low beta. This means that if you believe the current share price should move towards its intrinsic value over time, a low beta could suggest it is not likely to reach that level anytime soon, and once it’s there, it may be hard to fall back down into an attractive buying range again.

What does the future of NVLN look like?

NasdaqGS:NVLN Future Profit Nov 11th 17

Future outlook is an important aspect when you’re looking at buying a stock, especially if you are an investor looking for growth in your portfolio. Buying a great company with a robust outlook at a cheap price is always a good investment, so let’s also take a look at NVLN future expectations. In the upcoming year, NVLN’s earnings are expected to increase by 80.38%, indicating a highly optimistic future ahead. This should lead to more robust cash flows, feeding into a higher share value.

What this means for you:

Are you a shareholder? Since NVLN is currently undervalued, it may be a great time to increase your holdings in the stock. With an optimistic outlook on the horizon, it seems like this growth has not yet been fully factored into the share price. However, there are also other factors such as capital structure to consider, which could explain the current undervaluation.

Are you a potential investor? If you’ve been keeping an eye on NVLN for a while, now might be the time to make a leap. Its buoyant future outlook isn’t fully reflected in the current share price yet, which means it’s not too late to buy NVLN. But before you make any investment decisions, consider other factors such as the track record of its management team, in order to make a well-informed buy.

Price is just the tip of the iceberg. Dig deeper into what truly matters – the fundamentals – before you make a decision on Novelion Therapeutics. You can find everything you need to know about NVLN in the latest infographic research report. If you are no longer interested in Novelion Therapeutics, you can use our free platform to see my list of over 50 other stocks with a high growth potential.


To help readers see pass the short term volatility of the financial market, we aim to bring you a long-term focused research analysis purely driven by fundamental data. Note that our analysis does not factor in the latest price sensitive company announcements.

The author is an independent contributor and at the time of publication had no position in the stocks mentioned.